SWK Holdings

SWK deploys capital into two primary structures: royalty acquisitions, where the firm buys a percentage of a commercial product’s future revenue in exchange for upfront cash, and secured credit facilities including term loans and revolvers. Both are anchored to intellectual property and commercial-stage revenue streams, not to pre-revenue biotech assets. The firm targets companies with $5 million to $50 million in revenue, operating in pharmaceuticals, medical devices, diagnostics, and healthcare services, per public filings.

SWK is a public company — ticker SWKH on the NASDAQ — and does not operate as a private fund with limited partners. Its entire investment portfolio sits on a single corporate balance sheet, which functions as permanent capital. This eliminates the fundraising cycle and exit-timing pressure that define private credit and private equity fund models.

SWK targets commercial-stage life science and healthcare services companies generating positive revenue, with a strict avoidance of pre-revenue biotech. The portfolio spans branded and generic pharmaceuticals, medical devices, diagnostics, and select healthcare services. The company has historically avoided early-stage venture risk, instead focusing on products already generating royalty or sales income that can be monetized through structured transactions.

Yes, SWK maintains a smaller secondary business line providing credit to community and regional financial institutions, which diversifies its balance sheet away from pure healthcare royalty exposure. This non-healthcare lending is structured as traditional secured finance and does not carry the royalty upside feature of the core healthcare book.